Modelling the potential financial impacts of expanding access to immune checkpoint inhibitors as monotherapy for treating advanced non-small cell lung cancerResearch in context

Summary: Background: Access to immune checkpoint inhibitors remains limited due to cost-effectiveness and affordability concerns. This study evaluates the financial impacts of expanding global access to PD1/PD-L1 inhibitors as first-line monotherapy for patients aged 40–74 years with advanced unres...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Kiu Tay-Teo, Dario Trapani, Manju Sengar, Zeba Aziz, Filip Meheus, André Ilbawi, Elisabeth G.E. de Vries, Lorenzo Moja
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Elsevier 2025-06-01
Saila:	EClinicalMedicine
Gaiak:	Non-small cell lung cancer Immune checkpoint inhibitor Access to medicines Economics Finances
Sarrera elektronikoa:	http://www.sciencedirect.com/science/article/pii/S2589537025001932
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!